Ilumya FDA Approval History
FDA Approved: Yes (First approved March 20, 2018)
Brand name: Ilumya
Generic name: tildrakizumab-asmn
Dosage form: Injection
Company: Sun Pharmaceutical Industries Inc.
Treatment for: Plaque Psoriasis
Ilumya (tildrakizumab-asmn) is an interleukin-23 antagonist for the treatment of moderate-to-severe plaque psoriasis.
Development timeline for Ilumya
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.